Cost-effectiveness of noninvasive telemedical interventional management in patients with heart failure: health economic analysis of the TIM-HF2 trial.


Journal

Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 28 06 2021
accepted: 24 11 2021
pubmed: 12 12 2021
medline: 3 11 2022
entrez: 11 12 2021
Statut: ppublish

Résumé

Noninvasive remote patient management (RPM) in patients with heart failure (HF) has been shown to reduce the days lost due to unplanned cardiovascular hospital admissions and all-cause mortality in the Telemedical Interventional Management in Heart Failure II trial (TIM-HF2). The health economic implications of these findings are the focus of the present analyses from the payer perspective. A total of 1538 participants of the TIM-HF2 randomized controlled trial were assigned to the RPM and Usual Care group. Health claims data were available for 1450 patients (n = 715 RPM group, n = 735 Usual Care group), which represents 94.3% of the original TIM-HF2 patient population, were linked to primary data from the study documentation and evaluated in terms of the health care cost, total cost (accounting for intervention costs), costs per day alive and out of hospital (DAOH), and cost per quality-adjusted life year (QALY). The average health care costs per patient year amounted to € 14,412 (95% CI 13,284-15,539) in the RPM group and € 17,537 (95% CI 16,179-18,894) in the UC group. RPM led to cost savings of € 3125 per patient year (p = 0.001). After including the intervention costs, a cost saving of € 1758 per patient year remained (p = 0.048). The additional noninvasive telemedical interventional management in patients with HF was cost-effective compared to standard care alone, since such intervention was associated with overall cost savings and superior clinical effectiveness.

Sections du résumé

BACKGROUND BACKGROUND
Noninvasive remote patient management (RPM) in patients with heart failure (HF) has been shown to reduce the days lost due to unplanned cardiovascular hospital admissions and all-cause mortality in the Telemedical Interventional Management in Heart Failure II trial (TIM-HF2). The health economic implications of these findings are the focus of the present analyses from the payer perspective.
METHODS AND RESULTS RESULTS
A total of 1538 participants of the TIM-HF2 randomized controlled trial were assigned to the RPM and Usual Care group. Health claims data were available for 1450 patients (n = 715 RPM group, n = 735 Usual Care group), which represents 94.3% of the original TIM-HF2 patient population, were linked to primary data from the study documentation and evaluated in terms of the health care cost, total cost (accounting for intervention costs), costs per day alive and out of hospital (DAOH), and cost per quality-adjusted life year (QALY). The average health care costs per patient year amounted to € 14,412 (95% CI 13,284-15,539) in the RPM group and € 17,537 (95% CI 16,179-18,894) in the UC group. RPM led to cost savings of € 3125 per patient year (p = 0.001). After including the intervention costs, a cost saving of € 1758 per patient year remained (p = 0.048).
CONCLUSION CONCLUSIONS
The additional noninvasive telemedical interventional management in patients with HF was cost-effective compared to standard care alone, since such intervention was associated with overall cost savings and superior clinical effectiveness.

Identifiants

pubmed: 34894273
doi: 10.1007/s00392-021-01980-2
pii: 10.1007/s00392-021-01980-2
pmc: PMC9622523
doi:

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1231-1244

Subventions

Organisme : bundesministerium für bildung, wissenschaft, forschung und technologie
ID : 13KQ0904A
Organisme : bundesministerium für bildung, wissenschaft, forschung und technologie
ID : 13KQ0904B
Organisme : bundesministerium für bildung, wissenschaft, forschung und technologie
ID : 13KQ1104A

Informations de copyright

© 2021. The Author(s).

Références

Störk S, Handrock R, Jacob J et al (2017) Epidemiology of heart failure in Germany: a retrospective database study. Clin Res Cardiol 106(11):913–922. https://doi.org/10.1007/s00392-017-1137-7[publishedOnlineFirst:2017/07/28]
doi: 10.1007/s00392-017-1137-7[publishedOnlineFirst:2017/07/28] pubmed: 28748265 pmcid: 5655572
Holstiege J, Akmatov MK, Störk S et al (2019) Higher prevalence of heart failure in rural regions: a population-based study covering 87% of German inhabitants. Clin Res Cardiol 108(10):1102–1106. https://doi.org/10.1007/s00392-019-01444-8[publishedOnlineFirst:2019/02/25]
doi: 10.1007/s00392-019-01444-8[publishedOnlineFirst:2019/02/25] pubmed: 30798347
Deutscher Herzbericht, Deutsche Herzstiftung e.V., Frankfurt am Main, 2019
Statistisches Bundesamt, Krankheitskosten. Wiesbaden, 2015
Seferovic PM, Ponikowski P, Anker SD et al (2019) Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(10):1169–1186. https://doi.org/10.1002/ejhf.1531 (published Online First: 2019/05/28)
Gensini GF, Alderighi C, Rasoini R et al (2017) Value of telemonitoring and telemedicine in heart failure management. Card Fail Rev 3(2):116–121. https://doi.org/10.15420/cfr.2017:6:2 (published Online First: 2018/02/02)
doi: 10.15420/cfr.2017:6:2 pubmed: 29387464 pmcid: 5739893
Dierckx R, Inglis SC, Clark RA et al (2017) Telemedicine in heart failure: new insights from the Cochrane meta-analyses. Eur J Heart Fail 19(3):304–306. https://doi.org/10.1002/ejhf.759 (published Online First: 2017/03/03)
doi: 10.1002/ejhf.759 pubmed: 28251777
Diedrich L, Dockweiler C, Kupitz A et al (2018) Telemonitoring in heart failure: update on health-related and economic implications. Herz 43(4):298–309. https://doi.org/10.1007/s00059-017-4579-9 (published online First: 2017/06/09)
doi: 10.1007/s00059-017-4579-9 pubmed: 28593423
Inglis SC, Clark RA, Dierckx R et al (2017) Structured telephone support or non-invasive telemonitoring for patients with heart failure. Heart 103(4):255–257. https://doi.org/10.1136/heartjnl-2015-309191 (published Online First: 2016/11/20)
doi: 10.1136/heartjnl-2015-309191 pubmed: 27864319
Blum K, Gottlieb SS (2014) The effect of a randomized trial of home telemonitoring on medical costs, 30-day readmissions, mortality, and health-related quality of life in a cohort of community-dwelling heart failure patients. J Card Fail 20(7):513–521. https://doi.org/10.1016/j.cardfail.2014.04.016 (published Online First: 2014/04/29)
doi: 10.1016/j.cardfail.2014.04.016 pubmed: 24769270
Villani A, Malfatto G, Compare A et al (2014) Clinical and psychological telemonitoring and telecare of high risk heart failure patients. J Telemed Telecare 20(8):468–475. https://doi.org/10.1177/1357633x14555644 (published Online First: 2014/10/24)
doi: 10.1177/1357633x14555644 pubmed: 25339632
Vestergaard AS, Hansen L, Sørensen SS et al (2020) Is telehealthcare for heart failure patients cost-effective? An economic evaluation alongside the Danish TeleCare North heart failure trial. BMJ Open 10(1):e031670. https://doi.org/10.1136/bmjopen-2019-031670 (published Online First: 2020/01/30)
doi: 10.1136/bmjopen-2019-031670 pubmed: 31992604 pmcid: 7045102
Isaranuwatchai W, Redwood O, Schauer A et al (2018) A remote patient monitoring intervention for patients with chronic obstructive pulmonary disease and chronic heart failure: pre-post economic analysis of the smart program. JMIR Cardio 2(2):e10319. https://doi.org/10.2196/10319 (published Online First: 2019/11/24)
doi: 10.2196/10319 pubmed: 31758770 pmcid: 6834207
Voeller H, Bindl D, Nagels K et al (2017) Remote telemonitoring in chronic heart failure does not reduce healthcare cost but improves quality of life: Endpoints of the CARDIOBBEAT trail. J Am Coll Cardiol 69:672–772. https://doi.org/10.1016/S0735-1097(17)34061-5
doi: 10.1016/S0735-1097(17)34061-5
Cowie MR, Simon M, Klein L et al (2017) The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective. Eur J Heart Fail 19(5):661–669. https://doi.org/10.1002/ejhf.747 (published Online First: 2017/02/09)
doi: 10.1002/ejhf.747 pubmed: 28176424
Koehler F, Koehler K, Deckwart O et al (2018) Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet 392(10152):1047–1057. https://doi.org/10.1016/s0140-6736(18)31880-4 (published Online First: 2018/08/30)
doi: 10.1016/s0140-6736(18)31880-4 pubmed: 30153985
Koehler F, Koehler K, Deckwart O et al (2018) Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the intervention. Eur J Heart Fail 20(10):1485–1493. https://doi.org/10.1002/ejhf.1300 (published Online First: 2018/09/20)
doi: 10.1002/ejhf.1300 pubmed: 30230666
Dyer MT, Goldsmith KA, Sharples LS et al (2010) A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes 8:13. https://doi.org/10.1186/1477-7525-8-13 (published Online First: 2010/01/30)
doi: 10.1186/1477-7525-8-13 pubmed: 20109189 pmcid: 2824714
Richardson G, Manca A (2004) Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. Health Econ 13(12):1203–1210. https://doi.org/10.1002/hec.901 (published Online First: 2004/09/24)
doi: 10.1002/hec.901 pubmed: 15386669
Gregori D, Petrinco M, Bo S et al (2011) Regression models for analyzing costs and their determinants in health care: an introductory review. Int J Qual Health Care 23(3):331–341. https://doi.org/10.1093/intqhc/mzr010 (published Online First: 2011/04/21)
doi: 10.1093/intqhc/mzr010 pubmed: 21504959
Mihaylova B, Briggs A, O’Hagan A et al (2011) Review of statistical methods for analysing healthcare resources and costs. Health Econ 20(8):897–916. https://doi.org/10.1002/hec.1653 (published Online First: 2010/08/28)
doi: 10.1002/hec.1653 pubmed: 20799344
Streiner DL, Norman GR (2011) Correction for multiple testing: is there a resolution? Chest 140(1):16–18. https://doi.org/10.1378/chest.11-0523 (published Online First: 2011/07/07)
doi: 10.1378/chest.11-0523 pubmed: 21729890
Winkler S, Koehler K, Prescher S et al (2021) Is 24/7 remote patient management in heart failure necessary? Results of the telemedical emergency service used in the TIM-HF and in the TIM-HF2 trials. ESC Heart Fail. https://doi.org/10.1002/ehf2.13413
doi: 10.1002/ehf2.13413 pubmed: 34182596 pmcid: 8497196
Reinhold T, Brüggenjürgen B, Schlander M et al (2010) Economic analysis based on multinational studies: methods for adapting findings to national contexts. J Public Health 18(4):327–335
doi: 10.1007/s10389-010-0315-0
Gontarska K, Wrazen W, Beilharz J et al. (2021) Predicting medical interventions from vital parameters: towards a decision support system for remote patient monitoring. In: International Conference on Artificial Intelligence in Medicine, pp 293–97
Hiddemann M, Prescher S, Koehler K, Koehler F (2021) Telemedizin bei Herzinsuffizienz—translation von klinischen Studien in die Regelversorgung. Aktuelle Kardiologie. https://doi.org/10.1055/a-1506-5821
doi: 10.1055/a-1506-5821

Auteurs

Hanna Sydow (H)

Division of Health Economics and Health Services Research, Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Luisenstr. 57, 10117, Berlin, Germany. hanna.sydow@charite.de.

Sandra Prescher (S)

Centre for Cardiovascular Telemedicine, Medical Department, Division of Cardiology and Angiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Friedrich Koehler (F)

Centre for Cardiovascular Telemedicine, Medical Department, Division of Cardiology and Angiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Kerstin Koehler (K)

Centre for Cardiovascular Telemedicine, Medical Department, Division of Cardiology and Angiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Marc Dorenkamp (M)

Department of Cardiology (Campus Virchow-Klinikum), Charité-Universitätsmedizin Berlin, Berlin, Germany.

Sebastian Spethmann (S)

Department of Cardiology and Angiology (Campus Charité Mitte), Charité-Universitätsmedizin Berlin, Berlin, Germany.

Benjamin Westerhoff (B)

BARMER, Wuppertal, Germany.

Christoph J Wagner (CJ)

AOK Nordost-Die Gesundheitskasse, Health Services Management, Berlin, Germany.

Sebastian Liersch (S)

AOK Nordost-Die Gesundheitskasse, Health Services Management, Berlin, Germany.

Herbert Rebscher (H)

IGVresearch-Institut für Gesundheitsökonomie und Versorgungsforschung, Hamburg, Germany.
Faculty of Law, Business and Economics, University of Bayreuth, Bayreuth, Germany.

Stefanie Wobbe-Ribinski (S)

DAK Gesundheit, Health Services Research and Innovation, Hamburg, Germany.

Heike Rindfleisch (H)

Internal Medicine with Gastroenterology and Nephrology (CC 13), Charité-Universitätsmedizin Berlin, Berlin, Germany.

Falk Müller-Riemenschneider (F)

Division of Health Economics and Health Services Research, Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Luisenstr. 57, 10117, Berlin, Germany.
Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.

Stefan N Willich (SN)

Division of Health Economics and Health Services Research, Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Luisenstr. 57, 10117, Berlin, Germany.

Thomas Reinhold (T)

Division of Health Economics and Health Services Research, Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Luisenstr. 57, 10117, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH